Trial · NCT06210750
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT06210750, Phase 2, Withdrawn, National Cancer Institute (NCI)
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL). Trials, record NCT06210750. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06210750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT number
- NCT06210750
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- National Cancer Institute (NCI)
- Conditions
- T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
- Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography, Lumbar Puncture, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Navitoclax, Nelarabine, Pegaspargase, Positron Emission Tomography, Thioguanine, Venetoclax, Vincristine, X-Ray Imaging
- First posted
- 2024-01-18
- Last updated
- 2024-05-17
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of adverse events (Cohorts 1, 2 and 3) | Up to 10 years | National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events will be used to determine severity of toxicity. |
| Primary | Undetectable minimal residual disease (MRD) (Cohort 1) | At day 29 following induction | There will be three primary analyses, each comparing an experimental arm with the shared control arm using Fisher's exact test with a one-sided alpha of 10%. All eligible randomized participants will be used in the efficacy comparison. |
| Primary | Percent of participants with detectable disease in the bone marrow (Cohort 2) | At diagnosis and at days 29 and 57 | Binomial estimates will be reported along with exact 95% confidence intervals. |
| Primary | Undetectable MRD (Cohorts 1 and 3) | At days 29 and 78 | Binomial estimates will be reported along with exact 95% confidence intervals. |
| Secondary | Rate of complete remission (CR) | End of consolidation therapy | Response rates in each arm and cohort will be calculated and presented with exact binomial 95% confidence intervals. |
| Secondary | Rate of complete remission with incomplete count recovery (CRi) with and without MRD | End of consolidation therapy | Response rates in each arm and cohort will be calculated and presented with exact binomial 95% confidence intervals. |
| Secondary | Event free survival | From the date of initial registration on study until the first of the following events: death from any cause, relapse from MRD-negative remission, or completion of protocol therapy without documentation of MRD-negative remission, up to 10 years | Will be estimated using the method of Kaplan-Meier; randomized arms within Cohort 1 will be compared using the stratified log rank test. |
| Secondary | Relapse free survival | From the date the participant first achieves CR or CRi until relapse from CR/CRi or death from any cause, up to 10 years | Will be estimated using the method of Kaplan-Meier; randomized arms within Cohort 1 will be compared using the stratified log rank test. |
| Secondary | Overall survival | From the day of registration to death from any cause, up to 10 years | Will be estimated using the method of Kaplan-Meier; randomized arms within Cohort 1 will be compared using the stratified log rank test. |
| Secondary | Incidence of adverse events | Up to 10 years | National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events will be used to determine severity of toxicity. |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA180888 | SWOG Network Group Operations Center of the NCTN | LARA, PRIMO N.; HERSHMAN, DAWN | UNIVERSITY OF CALIFORNIA AT DAVIS | NATIONAL CANCER INSTITUTE | 2014 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06210750
GET https://conductscience.org/api/trials/v1/NCT06210750/registered